- Lymph Node Biopsy
- Immunophenotyping
- Cytogenetic Analysis
- Gene Expression Profiling
- Microarray analysis
- Physical Imaging
- MRI Scanning
- CT-Scan
- X-rays
- Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
- Blood Tests
Non-Hodgkin Lymphoma Diagnostics Market size was valued at USD 12149.12 million in 2021 and is expected to grow at a CAGR of 10.8% from 2023-2029. Several factors, such as AIDS infection, immunosuppressive medications, occupational exposures, pesticide proximity, and smoking, are key risk factors for the development of NHL. With around 4% of all cancer cases in the US, non-Hodgkin lymphoma (NHL) is one of the most prevalent tumours. According to the American Cancer Society, there will be an estimated, NHL will be identified in about 80,470 persons (44,120 men and 36,350 women). Adults and children are both included in this.
Non-Hodgkin lymphoma is the second most frequent cancer in people with HIV, and some people with AIDS also have lymphoma. It is true that non-Hodgkin lymphoma patients should routinely undergo HIV and hepatitis virus screenings. A thorough assessment of the burden brought on by malignancies was made by the Global Burden of Disease study (GBDs), which made it easier to monitor the temporal patterns in the disease burden. The idea that there is a connection between obesity and NHL has been supported by concurrent rises in the prevalence of obesity and the incidence of NHL during the past few decades. The prognosis for those who have non-lymphoma Hodgkin's has improved as a result of improvements in diagnosis and therapy. Researchers are investigating ways to avoid infections such HHV-8, HIV, HTLV-1, and H. pylori that have been linked to non-Hodgkin lymphoma. The chance of getting non-Hodgkin lymphoma may be decreased by avoiding exposure to certain substances, such as lead, arsenic, pesticides, vinyl chloride, and asbestos.
In May 2021, PerkinElmer, Inc. purchased Immunodiagnostic Systems Holdings PLC in order to grow its overall diagnostics business for about $155 million.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Growing awareness and concern about the disease, increase in healthcare expenditure, rise in advancements in the technologies and innovation of new products, large number of unmet needs related to the disease are the few factors which are propelling the growth of the Non-Hodgkin lymphoma diagnostics market. However, limited options for the treatment, inaccurate and inadequate results of the diagnosis, high cost associated with the tests are the few factors which are restraining the growth of the Non-Hodgkin lymphoma diagnostics market.
The Non-Hodgkin Lymphoma Diagnostics Market size was valued at USD 12149.12 million in 2021
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
The non hodgkin lymphoma diagnostics market key players are Novartis AG (Switzerland), Amgen, Inc.(U.S), Abbott Laboratories, Inc.(U.S), Eli Lilly and Company(U.S.), AstraZeneca plc (U.K)
1. Executive Summary |
2. Global Non-Hodgkin Lymphoma Diagnostics Market Introduction |
2.1. Global Non-Hodgkin Lymphoma Diagnostics Market - Taxonomy |
2.2. Global Non-Hodgkin Lymphoma Diagnostics Market - Definitions |
2.2.1. By Type |
2.2.2. By Type of NHL |
2.2.3. By Category of Condition |
2.2.4. By End User |
2.2.5. By Region |
3. Global Non-Hodgkin Lymphoma Diagnostics Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Key Developments |
4. Global Non-Hodgkin Lymphoma Diagnostics Market By Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
4.1. Lymph Node Biopsy |
4.1.1. Immunophenotyping |
4.1.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
4.1.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.1.1.3. Market Opportunity Analysis |
4.1.2. Cytogenetic Analysis |
4.1.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
4.1.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.1.2.3. Market Opportunity Analysis |
4.1.3. Gene Expression Profiling |
4.1.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
4.1.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.1.3.3. Market Opportunity Analysis |
4.1.4. Microarray Analysis |
4.1.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
4.1.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.1.4.3. Market Opportunity Analysis |
4.2. Physical Imaging |
4.2.1. MRI Scanning |
4.2.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
4.2.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.2.1.3. Market Opportunity Analysis |
4.2.2. CT-Scan |
4.2.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
4.2.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.2.2.3. Market Opportunity Analysis |
4.2.3. X-rays |
4.2.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
4.2.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.2.3.3. Market Opportunity Analysis |
4.2.4. Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) |
4.2.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
4.2.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.2.4.3. Market Opportunity Analysis |
4.3. Blood Tests |
4.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
4.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.3.3. Market Opportunity Analysis |
5. Global Non-Hodgkin Lymphoma Diagnostics Market By Type of NHL, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
5.1. B-Cell Non-Hodgkin Lymphoma |
5.1.1. Diffuse Large B-Cell Lymphoma |
5.1.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.1.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.1.3. Market Opportunity Analysis |
5.1.2. Burkitt Lymphoma |
5.1.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.1.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.2.3. Market Opportunity Analysis |
5.1.3. Mantel Cell Lymphoma |
5.1.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.1.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3.3. Market Opportunity Analysis |
5.1.4. Primary Central Nervous System Lymphoma |
5.1.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.1.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.4.3. Market Opportunity Analysis |
5.2. T-Cell Non-Hodgkin Lymphoma |
5.2.1. Peripheral T-Cell Lymphoma not Otherwise Specified |
5.2.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.2.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.1.3. Market Opportunity Analysis |
5.2.2. Anaplastic Large Cell Lymphoma |
5.2.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.2.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.2.3. Market Opportunity Analysis |
5.2.3. Angioimmunoblastic T-Cell Lymphoma |
5.2.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.2.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3.3. Market Opportunity Analysis |
5.2.4. Enteropathy-Associated T-Cell Lymphoma |
5.2.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.2.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.4.3. Market Opportunity Analysis |
5.2.5. Adult T-Cell Lymphoma |
5.2.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.2.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.5.3. Market Opportunity Analysis |
5.2.6. Nasal type NK/T-Cell Lymphoma |
5.2.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.2.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.5.3. Market Opportunity Analysis |
5.2.7. Hepatosplenic T-Cell Lymphoma |
5.2.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.2.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.5.3. Market Opportunity Analysis |
6. Global Non-Hodgkin Lymphoma Diagnostics Market By Category of Condition, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
6.1. Category A |
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Category B |
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Category X |
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Category E |
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7. Global Non-Hodgkin Lymphoma Diagnostics Market By End User, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
7.1. Hospitals |
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Diagnostic Centers |
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Clinics |
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8. Global Non-Hodgkin Lymphoma Diagnostics Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific |
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Latin America |
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. MEA |
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
8.6. Global Non-Hodgkin Lymphoma Diagnostics Market - Opportunity Analysis Index, By Type of NHL, Type, Category of Condition, End User, , , , and Region, 2023-2029 |
9. North America Non-Hodgkin Lymphoma Diagnostics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
9.1. Type Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1. Lymph Node Biopsy |
9.1.1.1. Immunophenotyping |
9.1.1.2. Cytogenetic Analysis |
9.1.1.3. Gene Expression Profiling |
9.1.1.4. Microarray Analysis |
9.1.2. Physical Imaging |
9.1.2.1. MRI Scanning |
9.1.2.2. CT-Scan |
9.1.2.3. X-rays |
9.1.2.4. Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) |
9.1.3. Blood Tests |
9.2. Type of NHL Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1. B-Cell Non-Hodgkin Lymphoma |
9.2.1.1. Diffuse Large B-Cell Lymphoma |
9.2.1.2. Burkitt Lymphoma |
9.2.1.3. Mantel Cell Lymphoma |
9.2.1.4. Primary Central Nervous System Lymphoma |
9.2.2. T-Cell Non-Hodgkin Lymphoma |
9.2.2.1. Peripheral T-Cell Lymphoma not Otherwise Specified |
9.2.2.2. Anaplastic Large Cell Lymphoma |
9.2.2.3. Angioimmunoblastic T-Cell Lymphoma |
9.2.2.4. Enteropathy-Associated T-Cell Lymphoma |
9.2.2.5. Adult T-Cell Lymphoma |
9.2.2.6. Nasal type NK/T-Cell Lymphoma |
9.2.2.7. Hepatosplenic T-Cell Lymphoma |
9.3. Category of Condition Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1. Category A |
9.3.2. Category B |
9.3.3. Category X |
9.3.4. Category E |
9.4. End User Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1. Hospitals |
9.4.2. Diagnostic Centers |
9.4.3. Clinics |
9.5. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.5.1. USA |
9.5.2. Canada |
10. Europe Non-Hodgkin Lymphoma Diagnostics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
10.1. Type Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Lymph Node Biopsy |
10.1.1.1. Immunophenotyping |
10.1.1.2. Cytogenetic Analysis |
10.1.1.3. Gene Expression Profiling |
10.1.1.4. Microarray Analysis |
10.1.2. Physical Imaging |
10.1.2.1. MRI Scanning |
10.1.2.2. CT-Scan |
10.1.2.3. X-rays |
10.1.2.4. Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) |
10.1.3. Blood Tests |
10.2. Type of NHL Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1. B-Cell Non-Hodgkin Lymphoma |
10.2.1.1. Diffuse Large B-Cell Lymphoma |
10.2.1.2. Burkitt Lymphoma |
10.2.1.3. Mantel Cell Lymphoma |
10.2.1.4. Primary Central Nervous System Lymphoma |
10.2.2. T-Cell Non-Hodgkin Lymphoma |
10.2.2.1. Peripheral T-Cell Lymphoma not Otherwise Specified |
10.2.2.2. Anaplastic Large Cell Lymphoma |
10.2.2.3. Angioimmunoblastic T-Cell Lymphoma |
10.2.2.4. Enteropathy-Associated T-Cell Lymphoma |
10.2.2.5. Adult T-Cell Lymphoma |
10.2.2.6. Nasal type NK/T-Cell Lymphoma |
10.2.2.7. Hepatosplenic T-Cell Lymphoma |
10.3. Category of Condition Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1. Category A |
10.3.2. Category B |
10.3.3. Category X |
10.3.4. Category E |
10.4. End User Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1. Hospitals |
10.4.2. Diagnostic Centers |
10.4.3. Clinics |
10.5. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.5.1. Germany |
10.5.2. France |
10.5.3. Italy |
10.5.4. Spain |
10.5.5. UK |
10.5.6. Rest of Europe |
11. Asia Pacific Non-Hodgkin Lymphoma Diagnostics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
11.1. Type Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Lymph Node Biopsy |
11.1.1.1. Immunophenotyping |
11.1.1.2. Cytogenetic Analysis |
11.1.1.3. Gene Expression Profiling |
11.1.1.4. Microarray Analysis |
11.1.2. Physical Imaging |
11.1.2.1. MRI Scanning |
11.1.2.2. CT-Scan |
11.1.2.3. X-rays |
11.1.2.4. Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) |
11.1.3. Blood Tests |
11.2. Type of NHL Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1. B-Cell Non-Hodgkin Lymphoma |
11.2.1.1. Diffuse Large B-Cell Lymphoma |
11.2.1.2. Burkitt Lymphoma |
11.2.1.3. Mantel Cell Lymphoma |
11.2.1.4. Primary Central Nervous System Lymphoma |
11.2.2. T-Cell Non-Hodgkin Lymphoma |
11.2.2.1. Peripheral T-Cell Lymphoma not Otherwise Specified |
11.2.2.2. Anaplastic Large Cell Lymphoma |
11.2.2.3. Angioimmunoblastic T-Cell Lymphoma |
11.2.2.4. Enteropathy-Associated T-Cell Lymphoma |
11.2.2.5. Adult T-Cell Lymphoma |
11.2.2.6. Nasal type NK/T-Cell Lymphoma |
11.2.2.7. Hepatosplenic T-Cell Lymphoma |
11.3. Category of Condition Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1. Category A |
11.3.2. Category B |
11.3.3. Category X |
11.3.4. Category E |
11.4. End User Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1. Hospitals |
11.4.2. Diagnostic Centers |
11.4.3. Clinics |
11.5. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.5.1. China |
11.5.2. Japan |
11.5.3. South Korea |
11.5.4. India |
11.5.5. Rest of APAC |
12. Latin America Non-Hodgkin Lymphoma Diagnostics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
12.1. Type Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Lymph Node Biopsy |
12.1.1.1. Immunophenotyping |
12.1.1.2. Cytogenetic Analysis |
12.1.1.3. Gene Expression Profiling |
12.1.1.4. Microarray Analysis |
12.1.2. Physical Imaging |
12.1.2.1. MRI Scanning |
12.1.2.2. CT-Scan |
12.1.2.3. X-rays |
12.1.2.4. Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) |
12.1.3. Blood Tests |
12.2. Type of NHL Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1. B-Cell Non-Hodgkin Lymphoma |
12.2.1.1. Diffuse Large B-Cell Lymphoma |
12.2.1.2. Burkitt Lymphoma |
12.2.1.3. Mantel Cell Lymphoma |
12.2.1.4. Primary Central Nervous System Lymphoma |
12.2.2. T-Cell Non-Hodgkin Lymphoma |
12.2.2.1. Peripheral T-Cell Lymphoma not Otherwise Specified |
12.2.2.2. Anaplastic Large Cell Lymphoma |
12.2.2.3. Angioimmunoblastic T-Cell Lymphoma |
12.2.2.4. Enteropathy-Associated T-Cell Lymphoma |
12.2.2.5. Adult T-Cell Lymphoma |
12.2.2.6. Nasal type NK/T-Cell Lymphoma |
12.2.2.7. Hepatosplenic T-Cell Lymphoma |
12.3. Category of Condition Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1. Category A |
12.3.2. Category B |
12.3.3. Category X |
12.3.4. Category E |
12.4. End User Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1. Hospitals |
12.4.2. Diagnostic Centers |
12.4.3. Clinics |
12.5. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.5.1. Brazil |
12.5.2. Mexico |
12.5.3. Argentina |
12.5.4. Rest of Latin America |
13. MEA Non-Hodgkin Lymphoma Diagnostics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
13.1. Type Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1. Lymph Node Biopsy |
13.1.1.1. Immunophenotyping |
13.1.1.2. Cytogenetic Analysis |
13.1.1.3. Gene Expression Profiling |
13.1.1.4. Microarray Analysis |
13.1.2. Physical Imaging |
13.1.2.1. MRI Scanning |
13.1.2.2. CT-Scan |
13.1.2.3. X-rays |
13.1.2.4. Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) |
13.1.3. Blood Tests |
13.2. Type of NHL Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1. B-Cell Non-Hodgkin Lymphoma |
13.2.1.1. Diffuse Large B-Cell Lymphoma |
13.2.1.2. Burkitt Lymphoma |
13.2.1.3. Mantel Cell Lymphoma |
13.2.1.4. Primary Central Nervous System Lymphoma |
13.2.2. T-Cell Non-Hodgkin Lymphoma |
13.2.2.1. Peripheral T-Cell Lymphoma not Otherwise Specified |
13.2.2.2. Anaplastic Large Cell Lymphoma |
13.2.2.3. Angioimmunoblastic T-Cell Lymphoma |
13.2.2.4. Enteropathy-Associated T-Cell Lymphoma |
13.2.2.5. Adult T-Cell Lymphoma |
13.2.2.6. Nasal type NK/T-Cell Lymphoma |
13.2.2.7. Hepatosplenic T-Cell Lymphoma |
13.3. Category of Condition Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1. Category A |
13.3.2. Category B |
13.3.3. Category X |
13.3.4. Category E |
13.4. End User Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1. Hospitals |
13.4.2. Diagnostic Centers |
13.4.3. Clinics |
13.5. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.5.1. GCC Countries |
13.5.2. South Africa |
13.5.3. Rest of MEA |
14. Competition Landscape |
14.1. Strategic Dashboard of Top Market Players |
14.2. Company Profiles (Introduction, Financial Analysis, By Product Offerings, Key Developments, Strategies, and SWOT Analysis) |
14.2.1. Novartis AG (Switzerland) |
14.2.2. Amgen, Inc.(U.S) |
14.2.3. Abbott Laboratories, Inc.(U.S) |
14.2.4. Eli Lilly and Company(U.S.) |
14.2.5. AstraZeneca plc (U.K) |
14.2.6. Illumina, Inc.(U.S) |
14.2.7. Genoptix, Inc. (U.S.) |
14.2.8. bioMeriux SA (France) |
14.2.9. Pfizer, Inc. (U.S.) |
14.2.10. Hoffmann-La Roche Ltd. (Switzerland) |
14.2.11. GlaxoSmithKline plc (UK) |
15. Research Methodology |
16. Key Assumptions and Acronyms |